[go: up one dir, main page]

PT3045206T - Derivado policíclico de carbamoilpiridona possuindo atividade inibidora de hiv-integrase - Google Patents

Derivado policíclico de carbamoilpiridona possuindo atividade inibidora de hiv-integrase

Info

Publication number
PT3045206T
PT3045206T PT161545314T PT16154531T PT3045206T PT 3045206 T PT3045206 T PT 3045206T PT 161545314 T PT161545314 T PT 161545314T PT 16154531 T PT16154531 T PT 16154531T PT 3045206 T PT3045206 T PT 3045206T
Authority
PT
Portugal
Prior art keywords
inhibitory activity
hiv integrase
integrase inhibitory
polycyclic carbamoylpyridone
carbamoylpyridone derivative
Prior art date
Application number
PT161545314T
Other languages
English (en)
Inventor
Alvin Johns Brian
Kawasuji Takashi
Taishi Teruhiko
Taoda Yoshiyuki
Original Assignee
Shionogi & Co
Viiv Healthcare Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37215098&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3045206(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shionogi & Co, Viiv Healthcare Co filed Critical Shionogi & Co
Publication of PT3045206T publication Critical patent/PT3045206T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT161545314T 2005-04-28 2006-04-28 Derivado policíclico de carbamoilpiridona possuindo atividade inibidora de hiv-integrase PT3045206T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005131161 2005-04-28
JP2005312076 2005-10-27

Publications (1)

Publication Number Publication Date
PT3045206T true PT3045206T (pt) 2018-07-05

Family

ID=37215098

Family Applications (5)

Application Number Title Priority Date Filing Date
PT17195280T PT3284520T (pt) 2005-04-28 2006-04-28 Derivado policíclico de carbamoílpiridona possuindo atividade inibidora de integrase do hiv
PT161545314T PT3045206T (pt) 2005-04-28 2006-04-28 Derivado policíclico de carbamoilpiridona possuindo atividade inibidora de hiv-integrase
PT181666215T PT3372281T (pt) 2005-04-28 2006-04-28 Derivado policíclico de carbamoilpiridona possuindo atividade inibidora de hiv-integrase
PT121590822T PT2465580E (pt) 2005-04-28 2006-04-28 Derivados de carbamoílpiridona policíclicos que possuem actividade inibitória de integrase de hiv
PT67588434T PT1874117E (pt) 2005-04-28 2006-04-28 Derivado policíclico de carbamoílpiridona possuindo actividade inibidora de hiv-integrasse

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT17195280T PT3284520T (pt) 2005-04-28 2006-04-28 Derivado policíclico de carbamoílpiridona possuindo atividade inibidora de integrase do hiv

Family Applications After (3)

Application Number Title Priority Date Filing Date
PT181666215T PT3372281T (pt) 2005-04-28 2006-04-28 Derivado policíclico de carbamoilpiridona possuindo atividade inibidora de hiv-integrase
PT121590822T PT2465580E (pt) 2005-04-28 2006-04-28 Derivados de carbamoílpiridona policíclicos que possuem actividade inibitória de integrase de hiv
PT67588434T PT1874117E (pt) 2005-04-28 2006-04-28 Derivado policíclico de carbamoílpiridona possuindo actividade inibidora de hiv-integrasse

Country Status (29)

Country Link
US (22) US8129385B2 (pt)
EP (9) EP3045206B2 (pt)
JP (2) JP4295353B2 (pt)
KR (4) KR101363875B1 (pt)
AU (1) AU2006239177B8 (pt)
BR (1) BRPI0610030B8 (pt)
CA (1) CA2606282C (pt)
CY (7) CY1115151T1 (pt)
DK (6) DK3284520T3 (pt)
EA (1) EA014162B1 (pt)
ES (7) ES2743531T3 (pt)
FI (1) FIC20210017I1 (pt)
FR (1) FR14C0041I2 (pt)
HK (4) HK1107227A1 (pt)
HU (6) HUE056603T2 (pt)
IL (4) IL186555A (pt)
LT (4) LT3045206T (pt)
LU (2) LU92446I2 (pt)
MA (1) MA29460B1 (pt)
MX (2) MX302718B (pt)
NL (2) NL300676I2 (pt)
NO (5) NO339525B1 (pt)
NZ (1) NZ562339A (pt)
PL (5) PL3372281T3 (pt)
PT (5) PT3284520T (pt)
SI (6) SI3045206T1 (pt)
TW (1) TWI378931B (pt)
VN (1) VN34404A1 (pt)
WO (1) WO2006116764A1 (pt)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060127909A (ko) 2003-12-24 2006-12-13 비오타 사이언티픽 매니지먼트 피티와이 엘티디 호흡기 다핵체 바이러스 감염 치료용 다환 물질
US7273859B2 (en) * 2004-05-12 2007-09-25 Bristol-Myers Squibb Company HIV integrase inhibitors: cyclic pyrimidinone compounds
EP3045206B2 (en) * 2005-04-28 2023-02-15 VIIV Healthcare Company Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity
CA2607151C (en) 2005-05-10 2012-06-19 Merck & Co., Inc. Hiv integrase inhibitors
JP5094725B2 (ja) 2005-10-04 2012-12-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ Ｈｉｖインテグラーゼ阻害剤
WO2007049675A1 (ja) * 2005-10-27 2007-05-03 Shionogi & Co., Ltd. Ｈｉｖインテグラーゼ阻害活性を有する多環性カルバモイルピリドン誘導体
TWI423972B (zh) 2006-09-28 2014-01-21 Biota Scient Management 治療呼吸系融合細胞病毒感染之多環劑
JP5269085B2 (ja) * 2007-11-15 2013-08-21 ギリアード サイエンシス インコーポレーテッド ヒト免疫不全ウイルス複製のインヒビター
PT2220076E (pt) 2007-11-15 2012-04-26 Gilead Sciences Inc Inibidores da replicação do vírus da imunodeficiência humana
US8354429B2 (en) 2007-11-16 2013-01-15 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
CN105198804B (zh) * 2008-07-25 2018-03-23 盐野义制药株式会社 用作hiv整合酶抑制剂的化合物
WO2010011818A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
HUE020489T4 (hu) * 2008-07-25 2016-01-28 Viiv Healthcare Co Dolutegravir elõvegyületek
WO2010011815A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
EP2465858B1 (en) 2008-07-25 2013-12-25 VIIV Healthcare Company Process for preparing a pyrido[1,2-a]pyrrolo[1',2':3,4]imidazo[1,2-d]pyrazine-8-carboxamide derivative
JP5572168B2 (ja) 2008-12-11 2014-08-13 ビーブ・ヘルスケア・カンパニー カルバモイルピリドンｈｉｖインテグラーゼ阻害剤の製造方法および中間体
US8624023B2 (en) 2008-12-11 2014-01-07 Shionogi & Co., Ltd. Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
JP5629268B2 (ja) * 2008-12-11 2014-11-19 塩野義製薬株式会社 マルトールエーテルの製造方法および中間体
AU2014277831C1 (en) * 2008-12-11 2022-10-06 Shionogi & Co. Ltd. Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
TR201808501T4 (tr) 2009-06-15 2018-07-23 Shionogi & Co Sübstitüe polisiklik karbamoilpiridon türevi.
WO2011011483A1 (en) * 2009-07-22 2011-01-27 Glaxosmithkline Llc Chemical compounds
JP5624148B2 (ja) 2009-10-13 2014-11-12 エランコ・アニマル・ヘルス・アイルランド・リミテッド 大環状インテグラーゼ阻害剤
AU2014202406C1 (en) * 2010-01-27 2019-03-07 Viiv Healthcare Company Antiviral therapy
EP3494972B1 (en) * 2010-01-27 2023-12-13 VIIV Healthcare Company Combinations of dolutegravir and lamivudine for the treatment of hiv infection
AU2014202404C1 (en) * 2010-01-27 2022-06-23 Viiv Healthcare Company Antiviral therapy
TWI508968B (zh) 2010-02-08 2015-11-21 Biota Scient Management 用於治療呼吸道融合性病毒感染的化合物
WO2011105590A1 (ja) * 2010-02-26 2011-09-01 日本たばこ産業株式会社 １，３，４，８－テトラヒドロ－２Ｈ－ピリド［１，２－ａ］ピラジン誘導体及びそのＨＩＶインテグラーゼ阻害剤としての利用
TWI582097B (zh) 2010-03-23 2017-05-11 Ｖｉｉｖ醫療保健公司 製備胺甲醯吡啶酮衍生物及中間體之方法
CN102958935B (zh) 2010-04-02 2015-12-09 爱尔兰詹森科学公司 大环整合酶抑制剂
JP5766690B2 (ja) * 2010-04-12 2015-08-19 塩野義製薬株式会社 インテグラーゼ阻害活性を有するピリドン誘導体
US9073941B2 (en) 2010-06-28 2015-07-07 Academia Sinica Compounds and methods for treating tuberculosis infection
PT2602260T (pt) 2010-08-05 2016-12-27 Shionogi & Co Processo para preparar composto possuindo atividade inibidora de integrase do vih
TWI577377B (zh) * 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
SI2620436T1 (en) * 2010-09-24 2018-08-31 Shionogi & Co., Ltd. A prodrug substituted polycyclic carbamoyl pyridone derivative
US8796303B2 (en) 2010-11-26 2014-08-05 Biota Scientific Management Pty Ltd. Imidazo[2,1-G][1,7]naphthyridines for treating respiratory syncytial virus infections
WO2012151361A1 (en) 2011-05-03 2012-11-08 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
EP2742051B1 (en) * 2011-09-14 2016-10-12 Mapi Pharma Limited Amorpous form of the dolutegravir sodium salt
WO2013054862A1 (ja) * 2011-10-12 2013-04-18 塩野義製薬株式会社 インテグラーゼ阻害活性を有する多環性ピリドン誘導体
ES2790358T3 (es) 2011-12-28 2020-10-27 Global Blood Therapeutics Inc Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular
JP6242810B2 (ja) 2011-12-28 2017-12-06 グローバル・ブラッド・セラピューティクス・インコーポレイテッドＧｌｏｂａｌ Ｂｌｏｏｄ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 置換ベンズアルデヒド化合物および組織酸素化の増加におけるそれらの使用方法
US9714243B2 (en) 2012-12-17 2017-07-25 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as HIV integrase inhibitors
TWI752457B (zh) * 2012-12-21 2022-01-11 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
MX2015008467A (es) * 2012-12-27 2015-09-23 Japan Tobacco Inc Derivado sustituido de espiropirido[1,2-a]pirazina y uso medico del mismo como inhibidor de la integrasa del virus de inmunodeficiencia humana.
CA2897137A1 (en) 2013-02-18 2014-08-21 Ratiopharm Gmbh Solid pharmaceutical dosage form of dolutegravir
EP2767272A1 (en) 2013-02-18 2014-08-20 Ratiopharm GmbH Solid pharmaceutical dosage form of dolutegravir
WO2014128545A2 (en) 2013-02-19 2014-08-28 Aurobindo Pharma Limited An improved process for the preparation of dolutegravir
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
MX378131B (es) 2013-03-15 2025-03-10 Global Blood Therapeutics Inc Compuestos y sus usos para modular la hemoglobina.
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
BR112015021985B1 (pt) 2013-03-15 2022-12-13 Global Blood Therapeutics, Inc Compostos ou sais farmaceuticamente aceitáveis dos mesmos, respectivos usos e composição
WO2014145040A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
KR101971385B1 (ko) 2013-03-15 2019-04-22 글로벌 블러드 테라퓨틱스, 인크. 헤모글로빈 조정을 위한 화합물 및 이의 용도
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9493479B2 (en) 2013-04-16 2016-11-15 Merck Sharp & Dohme Corp. Substituted pyrido[1,2-a]pyrazines as HIV integrase inhibitors
WO2014200880A1 (en) * 2013-06-13 2014-12-18 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
EP3016935B1 (en) * 2013-07-04 2018-09-05 Hetero Research Foundation Process for the preparation of intermediate of dolutegravir
NO2865735T3 (pt) * 2013-07-12 2018-07-21
PL3019503T3 (pl) 2013-07-12 2018-01-31 Gilead Sciences Inc Policykliczne związki karbamoilopirydonowe i ich zastosowanie do leczenia infekcji hiv
US9856270B2 (en) * 2013-07-17 2018-01-02 Ratiopharm Gmbh Dolutegravir salts
WO2015019310A1 (en) 2013-08-07 2015-02-12 Mylan Laboratories Ltd Process for the preparation of dolute-gravir and intermediates thereof
WO2015039348A1 (en) * 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
BR112016006651B8 (pt) 2013-09-27 2021-03-02 Merck Sharp & Dohme compostos derivados de quinolizina substituídos, composição farmacêutica que os compreende e uso dos referidos compostos
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
WO2015092752A1 (en) 2013-12-20 2015-06-25 Mylan Laboratories Ltd. Novel crystalline form of dolutegravir sodium
WO2015089847A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
WO2015108945A2 (en) 2014-01-14 2015-07-23 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
ES2770050T3 (es) * 2014-01-21 2020-06-30 Laurus Labs Ltd Nuevo procedimiento para la preparación de dolutegravir y sus sales farmacéuticamente aceptables
NZ715029A (en) 2014-02-07 2021-07-30 Global Blood Therapeutics Inc Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
CN105121409B (zh) * 2014-03-19 2017-05-24 杭州普晒医药科技有限公司 德罗格韦钠盐的晶型及其制备方法
WO2015140569A1 (en) 2014-03-20 2015-09-24 Cipla Limited Pharmaceutical composition
WO2015177537A1 (en) * 2014-05-20 2015-11-26 Cipla Limited Process for preparing polycyclic carbamoyl pyridone derivatives and intermediates thereof
TWI677489B (zh) * 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
NO2717902T3 (pt) 2014-06-20 2018-06-23
TW201613936A (en) * 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
US10011613B2 (en) 2014-08-22 2018-07-03 Shionogi & Co., Ltd. Polycyclic pyridone derivative having integrase inhibitory activity
EP3203995A4 (en) 2014-10-09 2019-05-15 Board of Regents of the University of Nebraska COMPOSITIONS AND METHODS OF DELIVERING THERAPY AGENTS
WO2016092527A1 (en) * 2014-12-12 2016-06-16 Sun Pharmaceutical Industries Limited A process for the preparation of dolutegravir
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
WO2016102078A1 (en) 2014-12-24 2016-06-30 Ratiopharm Gmbh Solid state forms of dolutegravir sodium
EP3045461A1 (en) 2015-01-16 2016-07-20 LEK Pharmaceuticals d.d. Processes for preparing dolutegravir and analogues thereof
CA2975884A1 (en) 2015-02-06 2016-08-11 Mylan Laboratories Limited Processes for the preparation of dolutegravir
CZ201599A3 (cs) 2015-02-13 2016-08-24 Zentiva, K.S. Pevné formy solí dolutegraviru a způsob jejich přípravy
WO2016154527A1 (en) * 2015-03-26 2016-09-29 Merck Sharp & Dohme Corp. Phosphate-substituted quinolizine derivatives useful as hiv integrase inhibitors
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
KR20190057158A (ko) * 2015-04-02 2019-05-27 길리애드 사이언시즈, 인코포레이티드 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도
CN112940010B (zh) * 2015-04-28 2021-11-02 盐野义制药株式会社 经取代的多环性吡啶酮衍生物及其前药
WO2016187788A1 (en) 2015-05-25 2016-12-01 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds useful for treating hiv infection
CZ2015537A3 (cs) 2015-08-04 2017-02-15 Zentiva, K.S. Pevné formy amorfního dolutegraviru
WO2017029642A2 (en) 2015-08-19 2017-02-23 Laurus Labs Private Limited Novel polymorphs of dolutegravir and salts thereof
MX2018005729A (es) 2015-11-09 2018-08-09 Gilead Sciences Inc Composiciones terapeuticas para tratamiento del virus de inmunodeficiencia humana.
US10548910B2 (en) 2015-11-17 2020-02-04 Merck Sharp & Dohme Corp. Amido-substituted pyridotriazine derivatives useful as HIV integrase inhibitors
BR112018011272A2 (pt) 2015-12-04 2018-11-21 Global Blood Therapeutics Inc regimes de dosagem para 2-hidróxi-6-((2-(1-isopropil-1h-pirazol-5-il)piridin-3-il)metóxi)benzaldeído
EP3389380B1 (en) 2015-12-15 2021-07-21 Merck Sharp & Dohme Corp. Spirocyclic quinolizine derivatives useful as hiv integrase inhibitors
EP3394069B1 (en) 2015-12-21 2019-05-22 Lupin Limited Process for the preparation of hiv integrase inhibitors
TWI825524B (zh) 2016-05-12 2023-12-11 美商全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
WO2017208105A1 (en) 2016-05-30 2017-12-07 Lupin Limited Novel crystalline form of dolutegravir sodium
US11117904B2 (en) 2016-06-23 2021-09-14 Viiv Healthcare Company Compositions and methods for the delivery of therapeutics
US11045423B2 (en) 2016-08-08 2021-06-29 Hetero Labs Limited Anti-retroviral compositions
ES2952878T3 (es) 2016-08-08 2023-11-06 Hetero Labs Ltd Una composición antirretroviral multiclase
AU2017310526B2 (en) * 2016-08-12 2021-08-12 Edwin J. Iwanowicz Protein kinase regulators
WO2018042332A1 (en) 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
WO2018057408A1 (en) * 2016-09-21 2018-03-29 Merck Sharp & Dohme Corp. Drug delivery system for the delivery of integrase inhibitors
TWI778983B (zh) 2016-10-12 2022-10-01 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
JOP20190130A1 (ar) * 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
JP2020500866A (ja) 2016-12-02 2020-01-16 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｈｉｖインテグラーゼ阻害剤として有用な三環式複素環化合物
WO2018109786A1 (en) 2016-12-16 2018-06-21 Cipla Limited Novel polymoprphs and salts of polycyclic carbamoyl pyridone derivatives
US10786488B2 (en) 2017-01-26 2020-09-29 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as HIV integrase inhibitors
US11040986B2 (en) 2017-02-16 2021-06-22 Sandoz Ag Crystalline forms of cabotegravir sodium
EP3363802B1 (en) 2017-02-16 2019-11-20 Sandoz AG Crystalline form of cabotegravir sodium
WO2019016679A1 (en) * 2017-07-18 2019-01-24 Viiv Healthcare Company COMBINATION THERAPY
AU2018304591A1 (en) 2017-07-21 2020-03-05 Janssen Sciences Ireland Unlimited Company Regimens for treating hiv infections and aids
EP3661940A1 (en) 2017-09-07 2020-06-10 Cipla Limited New polymorphs of dolutegravir sodium
AR113748A1 (es) 2017-10-06 2020-06-10 Shionogi & Co Proceso estereoselectivo para preparar derivados de piridona policíclicos sustituidos
EP3737359A4 (en) 2018-01-12 2021-11-03 Board of Regents of the University of Nebraska ANTIVIRAL MEDICINES AND FORMULATIONS OF THEM
WO2019159199A1 (en) 2018-02-16 2019-08-22 Cipla Limited Continues flow process for the preparation of active pharmaceutical ingredients - polycyclic carbamoyl pyridone derivatives and intermediates thereof
CA3132832A1 (en) 2018-04-09 2019-10-17 Howard E. Gendelman Antiviral prodrugs and formulations thereof
CN110526930B (zh) 2018-05-23 2022-06-03 莫云芬 抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用
CN112533922B (zh) 2018-05-31 2024-03-22 盐野义制药株式会社 多环吡啶酮衍生物
TWI820141B (zh) * 2018-05-31 2023-11-01 日商鹽野義製藥股份有限公司 衍生物
WO2019230858A1 (ja) 2018-05-31 2019-12-05 塩野義製薬株式会社 多環性カルバモイルピリドン誘導体
EP3820875B1 (en) 2018-07-12 2024-01-17 Laurus Labs Limited A process for purification of protected polycyclic carbamoylpyridone derivatives
WO2020072377A1 (en) 2018-10-01 2020-04-09 Global Blood Therapeutics, Inc. Modulators of hemoglobin for the treatment of sickle cell disease
CN113226319B (zh) 2018-10-22 2023-04-11 内布拉斯加大学董事会 抗病毒前药及其纳米制剂
WO2020112931A1 (en) 2018-11-29 2020-06-04 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and nanoformulations thereof
EP3938047B1 (en) 2019-03-22 2022-06-22 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
RU2717101C1 (ru) * 2019-06-03 2020-03-18 Андрей Александрович Иващенко Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения
US20200398978A1 (en) 2019-06-20 2020-12-24 Bell Helicopter Textron Inc. Low-drag rotor blade extension
US11248005B2 (en) 2019-07-08 2022-02-15 Lupin Limited Process for preparation of intermediates used for the synthesis of HIV integrase inhibitor
US20230059640A1 (en) 2019-11-28 2023-02-23 Shionogi & Co., Ltd. Prophylactic and therapeutic pharmaceutical agent for hiv infectious diseases characterized by comprising combination of integrase inhibitor and anti-hiv agent
AU2020402659A1 (en) 2019-12-09 2022-06-02 Viiv Healthcare Company Pharmaceutical compositions comprising cabotegravir
MX2022009871A (es) 2020-02-24 2022-08-19 Gilead Sciences Inc Compuestos tetraciclicos para tratar la infeccion por el virus de la inmunodeficiencia humana (vih).
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
JP2023539344A (ja) 2020-09-01 2023-09-13 ヴィーブ、ヘルスケア、カンパニー カボテグラビルおよびレボノルゲストレルの組合せ
WO2022079739A1 (en) 2020-10-14 2022-04-21 Cipla Limited Fixed dose compositions of cabotegravir and rilpivirine
JP2024500322A (ja) 2020-12-07 2024-01-09 ヴィーブ、ヘルスケア、カンパニー 併用療法
PE20231297A1 (es) 2021-01-19 2023-08-22 Gilead Sciences Inc Compuestos de piridotriazina sustituidos y usos de estos
CN117715908A (zh) 2021-06-03 2024-03-15 江苏恒瑞医药股份有限公司 具有整合酶抑制活性的吡啶酮化合物及其药用用途
CN114230579A (zh) * 2021-11-12 2022-03-25 南京艾迪医药科技有限公司 多环氨基甲酰基吡啶酮衍生物及其制备方法和药物组合物
JP2024542776A (ja) 2021-12-03 2024-11-15 ヴィーブ、ヘルスケア、カンパニー （ｒ）－３－アミノブタン－１－オールの合成方法
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
US20240270756A1 (en) * 2023-01-18 2024-08-15 Ascletis Bioscience Co., Ltd. Integrase Inhibitor and Use Thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959316A (en) * 1972-03-13 1976-05-25 Snam Progetti S.P.A. Procedure for propylene oxide synthesis
JPH0296506A (ja) * 1988-09-30 1990-04-09 Daicel Chem Ind Ltd 除草剤組成物
JP2551472B2 (ja) 1988-10-18 1996-11-06 ダイセル化学工業株式会社 ５−アルコキシ−γ−ピロン−３−カルボキサミド誘導体とその製造方法及び植物成長抑制剤
JP2533796B2 (ja) 1988-10-18 1996-09-11 ダイセル化学工業株式会社 ５−アルコキシピリジン−３−カルボキサミド誘導体とその製造方法及び植物成長抑制剤
JP2001526265A (ja) 1997-12-22 2001-12-18 ファルマシア・アンド・アップジョン・カンパニー 抗ウイルス剤としての４−ヒドロキシキノリン−３−カルボキサミドおよびヒドラジド
EP1297834A4 (en) † 2000-06-14 2007-05-09 Shionogi & Co ENZYME INHIBITOR HAVING TWO DIVALENT METAL IONS AS ACTIVE CENTERS
US6580562B2 (en) 2000-07-24 2003-06-17 Yazaki Corporation On-vehicle display unit
US6384263B1 (en) 2000-08-04 2002-05-07 E. I. Du Pont De Nemours And Company Process for making 3-hydroxyalkanelnitriles and conversion of the 3-hydroxyalkanelnitrile to an hydroxyaminoalkane
AU1532802A (en) 2000-10-12 2002-04-22 Merck & Co Inc Aza- and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors
JP2003032772A (ja) 2001-07-12 2003-01-31 Foster Electric Co Ltd 耳掛け式イヤホン
CN101513402B (zh) 2001-08-10 2012-03-21 盐野义制药株式会社 抗病毒药
ME00427B (me) 2001-10-26 2011-10-10 Msd Italia Srl N-supstituisani hidroksipiramidinon karboksamidni inhibitori hiv integraze
JP4351053B2 (ja) 2001-10-26 2009-10-28 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ジヒドロキシピリミジンカルボキサミド系ｈｉｖインテグラーゼ阻害薬
WO2003062204A1 (en) 2002-01-17 2003-07-31 Merck & Co., Inc. Hydroxynaphthyridinone carboxamides useful as hiv integrase inhibitors
US7109186B2 (en) 2002-07-09 2006-09-19 Bristol-Myers Squibb Company HIV integrase inhibitors
WO2004024693A1 (ja) 2002-08-13 2004-03-25 Shionogi & Co., Ltd. Ｈｉｖインテグラーゼ阻害活性を有するヘテロ環化合物
AU2003267098B2 (en) 2002-09-11 2008-11-20 Merck & Co., Inc. Dihydroxypyridopyrazine-1,6-dione compounds useful as HIV integrase inhibitors
JP4733986B2 (ja) 2002-12-27 2011-07-27 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ＨＩＶインテグラーゼ阻害薬として有用なテトラヒドロ−４Ｈ−ピリド［１，２−ａ］ピリミジン類および関連する化合物
US6960680B2 (en) 2003-01-08 2005-11-01 Rhodia Chirex, Inc. Manufacture of water-soluble β-hydroxynitriles
JP2004244320A (ja) 2003-02-10 2004-09-02 Shionogi & Co Ltd 含窒素複素環抗ウイルス剤
JP2006528694A (ja) 2003-05-13 2006-12-21 スミスクライン ビーチャム コーポレーション ナフチリジンインテグラーゼインヒビター
WO2005015927A1 (en) * 2003-08-12 2005-02-17 Rachel Beijer Scheduled message service
TW200510425A (en) * 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
JP4530642B2 (ja) 2003-10-31 2010-08-25 オリンパス株式会社 内視鏡装置
BRPI0507628A (pt) 2004-02-11 2007-07-03 Smithkline Beecham Corp composto ou sal farmaceuticamente aceitável do mesmo, método de tratamento de uma infecção viral em um ser humano, uso de um composto composição farmacêutica, e, processo para a preparação de um composto
CA2557785A1 (en) † 2004-03-09 2005-10-06 Merck & Co. Inc. Hiv integrase inhibitors
JP2007528379A (ja) 2004-03-09 2007-10-11 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー Ｈｉｖインテグラーゼ阻害薬
JP4824673B2 (ja) 2004-05-07 2011-11-30 メルク・シャープ・エンド・ドーム・コーポレイション Ｈｉｖインテグラーゼ阻害剤
EP1973906A1 (en) 2004-12-23 2008-10-01 Virochem Pharma Inc. Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase
JP5317257B2 (ja) * 2005-02-21 2013-10-16 塩野義製薬株式会社 Ｈｉｖインテグラーゼ阻害活性を有する２環性カルバモイルピリドン誘導体
CA2600832C (en) * 2005-03-31 2011-12-13 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Hiv integrase inhibitors
EP3045206B2 (en) * 2005-04-28 2023-02-15 VIIV Healthcare Company Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity
JP2005312076A (ja) 2005-05-26 2005-11-04 Olympus Corp 電子撮像装置
US20080214527A1 (en) 2005-08-04 2008-09-04 Takashi Kawasuji Hiv Integrase Inhibitors
WO2007049675A1 (ja) 2005-10-27 2007-05-03 Shionogi & Co., Ltd. Ｈｉｖインテグラーゼ阻害活性を有する多環性カルバモイルピリドン誘導体

Also Published As

Publication number Publication date
EP3187226A1 (en) 2017-07-05
IL186555A (en) 2016-10-31
CY1116331T1 (el) 2017-02-08
EA200702080A1 (ru) 2008-04-28
EP3372281A1 (en) 2018-09-12
ES2743531T3 (es) 2020-02-19
JP4295353B2 (ja) 2009-07-15
KR101580310B1 (ko) 2016-01-04
ES2667868T3 (es) 2018-05-14
EP3284520B1 (en) 2019-06-05
DK2465580T3 (en) 2014-03-10
CY1120345T1 (el) 2019-07-10
NL300676I2 (pt) 2016-10-11
EP2527007B1 (en) 2016-03-30
BRPI0610030B8 (pt) 2022-01-11
PL3284520T3 (pl) 2020-01-31
HK1249742A1 (zh) 2018-11-09
AU2006239177A1 (en) 2006-11-02
EP3187225A1 (en) 2017-07-05
US20160304535A1 (en) 2016-10-20
US20220213121A1 (en) 2022-07-07
EP3284519A8 (en) 2018-04-18
DK1874117T3 (da) 2013-09-23
ES2906792T3 (es) 2022-04-20
JP2009079058A (ja) 2009-04-16
CY2021016I2 (el) 2021-12-31
EP3372281B1 (en) 2021-07-07
DK3372281T3 (da) 2021-09-27
BRPI0610030A2 (pt) 2011-10-11
LT3045206T (lt) 2018-06-11
PT3284520T (pt) 2019-09-10
SI3045206T1 (en) 2018-07-31
KR101848819B1 (ko) 2018-04-16
MA29460B1 (fr) 2008-05-02
IL186555A0 (en) 2008-01-20
EP3187225B1 (en) 2022-01-05
US20170253616A1 (en) 2017-09-07
IL225206A (en) 2017-11-30
US20160137666A1 (en) 2016-05-19
PL3372281T3 (pl) 2021-12-27
US20170209454A1 (en) 2017-07-27
LU92446I2 (fr) 2015-10-29
FR14C0041I2 (fr) 2015-11-13
HK1172282A1 (en) 2013-04-19
NO340111B1 (no) 2017-03-13
SI3284520T1 (sl) 2019-10-30
US20170224694A1 (en) 2017-08-10
HUS2100022I1 (hu) 2021-07-28
PL2465580T3 (pl) 2014-05-30
US20140200209A1 (en) 2014-07-17
US10927129B2 (en) 2021-02-23
US20170369509A1 (en) 2017-12-28
ES2437268T3 (es) 2014-01-09
EP2527007A1 (en) 2012-11-28
US8129385B2 (en) 2012-03-06
HK1251191A1 (zh) 2019-01-25
ES2892304T3 (es) 2022-02-03
NO2023042I1 (no) 2023-11-08
LUC00210I2 (pt) 2022-10-07
CY2014024I1 (el) 2015-12-09
CY2021016I1 (el) 2021-10-15
HUE056603T2 (hu) 2022-02-28
NZ562339A (en) 2011-01-28
HUS2100023I1 (hu) 2021-07-28
NO20161315A1 (no) 2007-11-22
VN34404A1 (en) 2013-07-25
LTPA2021512I1 (pt) 2021-07-12
US9273065B2 (en) 2016-03-01
US20170267693A1 (en) 2017-09-21
CY1122052T1 (el) 2020-10-14
US8778943B2 (en) 2014-07-15
MX312216B (en) 2013-08-12
WO2006116764A1 (en) 2006-11-02
ES2446324T3 (es) 2014-03-07
TW200716635A (en) 2007-05-01
EP3045206B2 (en) 2023-02-15
NL301109I2 (nl) 2021-09-15
US20170224695A1 (en) 2017-08-10
BRPI0610030B1 (pt) 2020-09-15
LT3284520T (lt) 2019-09-25
JP2008540343A (ja) 2008-11-20
NO20075165L (no) 2007-11-22
AU2006239177B8 (en) 2012-02-16
EP3284520A1 (en) 2018-02-21
EP2465580A1 (en) 2012-06-20
US9051337B2 (en) 2015-06-09
ES2567197T3 (es) 2016-04-20
SI1874117T1 (sl) 2014-01-31
US20090318421A1 (en) 2009-12-24
PT1874117E (pt) 2013-10-17
US11267823B2 (en) 2022-03-08
CY2014024I2 (el) 2015-12-09
IL225207A (en) 2017-11-30
IL215788A0 (en) 2011-12-29
CY1115151T1 (el) 2015-12-09
HUE037795T2 (hu) 2018-09-28
EP3045206A1 (en) 2016-07-20
US20240279238A1 (en) 2024-08-22
HUS1400039I1 (hu) 2016-08-29
EP1874117A1 (en) 2008-01-09
PL1874117T3 (pl) 2014-01-31
NO339525B1 (no) 2016-12-27
FIC20210017I1 (fi) 2021-06-10
KR101504998B1 (ko) 2015-03-23
US20190284208A1 (en) 2019-09-19
US20190152990A1 (en) 2019-05-23
US20130172559A1 (en) 2013-07-04
AU2006239177B2 (en) 2011-10-20
NO2017010I2 (no) 2017-03-27
PL3045206T3 (pl) 2018-08-31
ES2667868T5 (es) 2023-06-01
EP2465580B1 (en) 2013-12-18
US20200339598A1 (en) 2020-10-29
EA014162B1 (ru) 2010-10-29
US20120115875A1 (en) 2012-05-10
US20160207939A1 (en) 2016-07-21
LT3372281T (lt) 2021-12-10
CY1124601T1 (el) 2022-07-22
SI3372281T1 (sl) 2021-11-30
KR20140097438A (ko) 2014-08-06
CA2606282C (en) 2016-04-26
EP1874117A4 (en) 2009-12-30
KR20130133061A (ko) 2013-12-05
DK3187225T3 (da) 2022-02-28
PT2465580E (pt) 2014-02-25
FR14C0041I1 (pt) 2014-06-27
US20170145033A1 (en) 2017-05-25
NO2021018I1 (no) 2021-05-10
EP1874117B1 (en) 2013-08-28
SI2465580T1 (sl) 2014-04-30
EP3284519A1 (en) 2018-02-21
US20170260203A1 (en) 2017-09-14
EP3045206B1 (en) 2018-03-28
LTC2465580I2 (pt) 2022-10-10
DK3284520T3 (da) 2019-09-16
DK3045206T3 (en) 2018-05-22
HK1107227A1 (en) 2008-04-03
EP1874117B8 (en) 2014-03-12
SI3187225T1 (sl) 2022-04-29
US20170029438A1 (en) 2017-02-02
HUE044978T2 (hu) 2019-11-28
KR20080009733A (ko) 2008-01-29
MX2007013351A (es) 2008-01-21
CA2606282A1 (en) 2006-11-02
KR20160003889A (ko) 2016-01-11
US8410103B2 (en) 2013-04-02
TWI378931B (en) 2012-12-11
PT3372281T (pt) 2021-10-14
NL301109I1 (nl) 2021-09-15
NO2017010I1 (no) 2017-03-27
KR101363875B1 (ko) 2014-02-21
US20150232479A1 (en) 2015-08-20
MX302718B (es) 2012-08-27

Similar Documents

Publication Publication Date Title
HUS2100023I1 (hu) HIV integráz inhibitor hatású policiklusos karbamoil-piridon származékok
IL190879A0 (en) Polycyclic carbamoylpyridone derivative having inhibitory activity on hiv integrase
EP1790638A4 (en) CARBAMOYLPYRIDONE DERIVATIVE HAVING INHIBITION OF HIV INTEGRASE ACTIVITY
ZA200803423B (en) Polycyclic carbamoylpyridone derivative having inhibitory activity on HIV integrase
PL1948666T3 (pl) Inhibitory integrazy HIV
EP1725535A4 (en) HIV integrase
EP1910363A4 (en) INHIBITORS OF HIV INTEGRASE
EP1725102A4 (en) HIV integrase
EP1915181A4 (en) NEW HIV TARGETS
EP1910356A4 (en) HIV integrase
IL189939A0 (en) Inhibitors of the hiv integrase enzyme
EP1910355A4 (en) HIV integrase
EP1909578A4 (en) INHIBITORS OF HIV INTEGRASE